Navigation Links
Late-breaking observational data show patients with type 2 diabetes taking JANUVIA® (sitagliptin) and metformin initiated insulin therapy at a slower rate compared to patients taking a sulfonylurea and metformin
Date:6/14/2014

WHITEHOUSE STATION, N.J., June 14, 2014 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from a late-breaking observational study that assessed the differences in time to initiation of insulin use and the proportion of the population initiating insulin among patients with type 2 diabetes taking the combination of JANUVIA (sitagliptin) and metformin, and patients taking the combination of a sulfonylurea and metformin. In this study, patients treated with a combination of JANUVIA and metformin initiated insulin therapy at a slower rate during the period of observation than patients treated with a combination of sulfonylurea and metformin.

"Type 2 diabetes is a progressive disease, so that over time many patients need to add insulin to their treatment regimens to maintain blood sugar control," said Peter Stein, M.D., vice president, Clinical Research for diabetes and endocrinology, Merck Research Laboratories. "This study provides insight about different oral treatment regimens and their possible effect on initiation of insulin under real-world conditions. Real-world research is an important complement to clinical trials as we seek to improve patient health outcomes."

JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes mellitus. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. JANUVIA has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while taking JANUVIA. JANUVIA is contraindicated in patients with a history of a serious hypersensitivity reaction to sitagliptin, such as anaphylaxis or angioedema.

Results from "Assessing time to insulin use among type 2 diabetes patients treated with sitagliptin or sulfonylurea plus metformin dual therapy"
'/>"/>

Contact: Pam Eisele
267-305-3558

Kim Hamilton
908-423-6831

Justin Holko
908-423-5088

Merck
Source:Eurekalert


Page: 1 2 3 4 5

Related medicine news :

1. Hot Line IV: Late-breaking trials on heart failure and acute coronary syndrome
2. A large, observational study of common gout treatment allopurinol shows less than half of patients reach recommended treatment goal
3. New post-hoc analysis shows patients with type 2 diabetes undergoing intensification of insulin therapy experienced less nighttime hypoglycemia while being treated with Januvia (Sitagliptin) compared to placebo
4. BRCA test results affect patients breast cancer surgery plans
5. Genotyping can predict disease outcomes in rheumatoid arthritis patients
6. Ipilimumab in advanced melanoma: added benefit for non-pretreated patients not proven
7. Recreational football can treat hypertensive and type 2 diabetes patients
8. Low cholesterol linked with worse survival in patients with kidney cancer
9. One-third of psoriatic arthritis patients are not receiving optimal dosing of adalimumab
10. Higher disease activity scores in obese RA patients
11. First clinical diabetes registry to provide seamless view of patients across specialties
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... NJ (PRWEB) January 22, 2015 Joan ... and keynote speaker at the upcoming 32nd Annual ... ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , shares ... would have gone undetected if she had not followed ...
(Date:1/22/2015)... Four years since the release of their debut recording Love ... of Avasa & Matthew Love – the duo are pleased to ... through White Swan Records on February 24, 2015. , THE ROAD ... available to all of us to walk out of the mire ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... Global,s shared e-clinical service desk expands support to another ... leading ... Inc. (Nasdaq: TEAM ), a worldwide provider of information ... its subsidiary, TechTeam Global nv/sa, has been selected by,sanofi-aventis recherche ...
... MA--Researchers from Boston University School of Medicine have developed ... cancer. The model combines a specific gene expression ... These findings currently appear on-line in the journal ... leading cause of cancer death in the United States ...
... CHAPEL HILL, N.C., April 1, 2008 Faced ... forces are,having a challenging time serving the hospital ... to shrink, sales reps for the,pharma industry are ... win a place on formularies, according to research ...
... with Guaranteed Withdrawal Benefit, Turns Assets from Retirement ... ... Fortune 1000 Employees, NEW YORK, April 1, 2008 ... variable annuities,today launched a new variable annuity -- Crossings(SM): My ...
... Many top-selling drugs used to treat cancer and ... which are found in nature but historically difficult for ... For the first time, scientists at UC Irvine have ... easier for chemists to manipulate them into new drugs. ...
... 2008) Many patients who come to the ... are already taking 75mg of clopidogrel daily to ... 600-mg reloading dose of clopidogrel significantly improves clinical ... in patients with acute coronary syndromes (ACS), according ...
Cached Medicine News:Health News:TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement 2Health News:TechTeam Global Will Provide Multilingual EDC Support Services for sanofi-aventis recherche & developpement 3Health News:Researchers develop new method to test for lung cancer 2Health News:Effectively Influencing the Hospital Marketplace to Win a Place on Formularies 2Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 2Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 3Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 4Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 5Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 6Health News:AXA Equitable Unveils Crossings(SM): My Lifetime IRA(SM) 7Health News:Scientists solve mystery of polyketide drug formation 2Health News:Clopidogrel reloading worthwhile in acute coronary syndromes 2
(Date:1/23/2015)... N.J. , Jan. 23, 2015  CytoSorbents Corporation ... commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce ... announced the receipt of $385,642, net of transaction ... of the Technology Business Tax Certificate Transfer Program ...
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. (NYSE ... specializes in the development and sale of patented biopharmaceutical ... active pharmaceutical ingredients (API) today announced the business and ... operation. 1. Following the September 2014 JCM ...
(Date:1/22/2015)... Jan. 22, 2015  ResMed Inc. (NYSE: RMD ) ... Revenue for the quarter was $423.0 million, a 10 percent ... 14 percent increase on a constant currency basis). Net income ... the quarter ended December 31, 2013. Diluted earnings per share ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... 21, 2011  BARRX Medical Inc., a leader in developing ... to remove precancerous tissue from the gastrointestinal tract, announces ... be acquired by Covidien.  Covidien is a leading global ... advanced energy-based devices.  Covidien will acquire ...
... NORRITON, Pa., Nov. 21, 2011 Tengion, Inc. (NASDAQ: ... today announced that Brian Davis, Vice President Finance and ... upcoming Piper Jaffray 23rd Annual Health Care Conference on ... A live audio webcast of the presentation ...
Cached Medicine Technology:BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 2BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 3Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference 2
For the quantitative determination of uric acid in serum....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
For the quantitative determination of Uric Acid in serum. Linearity: 25 mg/dl....
... A fully automated, random ... over 50 assays available ... tumor marker, therapeutic drug, ... testing can be performed ...
Medicine Products: